Bluejay Diagnostics Completes Commercial Production of IL-6 Antibodies, Supporting 9 Million Symphony Cartridges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 29 2025
0mins
Should l Buy BJDX?
Source: Newsfilter
- Antibody Production Completed: Bluejay Diagnostics has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), meeting internal performance criteria and marking a significant advancement in inflammatory and critical care applications.
- Capacity Support: The company estimates that its current antibody inventory can support the production of over nine million Symphony™ cartridges, demonstrating its robust capabilities in clinical and commercial manufacturing to meet future market demands.
- Intellectual Property Strategy: Bluejay intends to utilize antibodies produced from its proprietary immunogen for ongoing development activities, aiming to enhance its intellectual property strategy and drive future product commercialization.
- Product Development Progress: Although the Symphony™ system remains under development and subject to further validation and regulatory review, the company has showcased its potential in rapid testing and disease progression monitoring, which is expected to improve patient outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BJDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BJDX
About BJDX
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
- Reverse Stock Split Announcement: Bluejay Diagnostics has announced a 1-for-4 reverse stock split effective January 29, which will reduce its outstanding shares from approximately 2.83 million to about 708,533, aimed at increasing share price to meet listing requirements.
- Stock Price Reaction: Following the reverse split announcement, Bluejay's shares fell 2.66% in pre-market trading to $0.77, indicating market concerns regarding the company's financial health, which could impact investor confidence.
- New CUSIP Number: The new CUSIP number for Bluejay's shares post-split will be 095633608, facilitating investor identification of the stock and ensuring smooth trading operations.
- Cash Payment for Fractional Shares: The company will provide cash payments to shareholders in lieu of any fractional shares resulting from the reverse split, a measure designed to mitigate potential losses for shareholders and protect their interests.
See More
Bluejay Diagnostics Completes Commercial Production of IL-6 Antibodies, Supporting 9 Million Symphony Cartridges
- Antibody Production Completed: Bluejay Diagnostics has successfully completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), meeting internal performance criteria for use in Symphony™ cartridge manufacturing for clinical and potential commercial applications.
- Sufficient Inventory: The company estimates that its current antibody inventory can support the production of over nine million Symphony cartridges, ensuring ample material supply for clinical and commercial manufacturing, thereby enhancing its market competitiveness.
- Intellectual Property Strategy: Bluejay intends to utilize antibodies produced from its proprietary immunogen for ongoing development activities, reinforcing its position in the medical diagnostics field through a robust intellectual property strategy.
- Future Development Potential: Although the Symphony™ system is still under development and requires further validation and regulatory review, its design aims to provide rapid test results in approximately 20 minutes, assisting medical professionals in making earlier decisions, which presents significant market potential.
See More
Bluejay Diagnostics Completes Commercial Production of IL-6 Antibodies, Supporting 9 Million Symphony Cartridges
- Antibody Production Completed: Bluejay Diagnostics has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), meeting internal performance criteria and marking a significant advancement in inflammatory and critical care applications.
- Capacity Support: The company estimates that its current antibody inventory can support the production of over nine million Symphony™ cartridges, demonstrating its robust capabilities in clinical and commercial manufacturing to meet future market demands.
- Intellectual Property Strategy: Bluejay intends to utilize antibodies produced from its proprietary immunogen for ongoing development activities, aiming to enhance its intellectual property strategy and drive future product commercialization.
- Product Development Progress: Although the Symphony™ system remains under development and subject to further validation and regulatory review, the company has showcased its potential in rapid testing and disease progression monitoring, which is expected to improve patient outcomes.
See More
Bluejay Diagnostics Completes $4.5 Million At-The-Market Private Placement in Accordance with Nasdaq Regulations
Private Placement Announcement: Bluejay Diagnostics, Inc. has completed a private placement of 2,250,000 shares of common stock and Series F warrants, raising $4.5 million to fund FDA approval processes and research activities.
Product Development Focus: The company is developing the Symphony System for rapid sepsis testing, with its first product candidate, an IL-6 Test, aimed at providing quick and reliable results to improve patient triage and treatment decisions.
See More
Bluejay Diagnostics Unveils $4.5 Million Private Placement Offered at Market Price According to Nasdaq Regulations
Private Placement Announcement: Bluejay Diagnostics, Inc. has entered into agreements to sell 2,250,000 shares of common stock and Series F warrants to purchase up to 4,500,000 shares at a price of $2.00 per share, with expected gross proceeds of $4.5 million.
Use of Proceeds: The company plans to use the net proceeds for FDA approval processes, clinical studies, research and development activities, and general working capital needs.
See More
Thursday's Major Stock Market Highlights: Morning News Summary!
Market Overview: Investors are navigating the second half of the week with a focus on significant stock market developments.
TipRanks Coverage: TipRanks provides a comprehensive list of the most notable market stories for Thursday.
See More
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
- Reverse Stock Split Announcement: Bluejay Diagnostics has announced a 1-for-4 reverse stock split effective January 29, which will reduce its outstanding shares from approximately 2.83 million to about 708,533, aimed at increasing share price to meet listing requirements.
- Stock Price Reaction: Following the reverse split announcement, Bluejay's shares fell 2.66% in pre-market trading to $0.77, indicating market concerns regarding the company's financial health, which could impact investor confidence.
- New CUSIP Number: The new CUSIP number for Bluejay's shares post-split will be 095633608, facilitating investor identification of the stock and ensuring smooth trading operations.
- Cash Payment for Fractional Shares: The company will provide cash payments to shareholders in lieu of any fractional shares resulting from the reverse split, a measure designed to mitigate potential losses for shareholders and protect their interests.
See More
Bluejay Diagnostics Completes Commercial Production of IL-6 Antibodies, Supporting 9 Million Symphony Cartridges
- Antibody Production Completed: Bluejay Diagnostics has successfully completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), meeting internal performance criteria for use in Symphony™ cartridge manufacturing for clinical and potential commercial applications.
- Sufficient Inventory: The company estimates that its current antibody inventory can support the production of over nine million Symphony cartridges, ensuring ample material supply for clinical and commercial manufacturing, thereby enhancing its market competitiveness.
- Intellectual Property Strategy: Bluejay intends to utilize antibodies produced from its proprietary immunogen for ongoing development activities, reinforcing its position in the medical diagnostics field through a robust intellectual property strategy.
- Future Development Potential: Although the Symphony™ system is still under development and requires further validation and regulatory review, its design aims to provide rapid test results in approximately 20 minutes, assisting medical professionals in making earlier decisions, which presents significant market potential.
See More
Bluejay Diagnostics Completes Commercial Production of IL-6 Antibodies, Supporting 9 Million Symphony Cartridges
- Antibody Production Completed: Bluejay Diagnostics has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), meeting internal performance criteria and marking a significant advancement in inflammatory and critical care applications.
- Capacity Support: The company estimates that its current antibody inventory can support the production of over nine million Symphony™ cartridges, demonstrating its robust capabilities in clinical and commercial manufacturing to meet future market demands.
- Intellectual Property Strategy: Bluejay intends to utilize antibodies produced from its proprietary immunogen for ongoing development activities, aiming to enhance its intellectual property strategy and drive future product commercialization.
- Product Development Progress: Although the Symphony™ system remains under development and subject to further validation and regulatory review, the company has showcased its potential in rapid testing and disease progression monitoring, which is expected to improve patient outcomes.
See More
Bluejay Diagnostics Completes $4.5 Million At-The-Market Private Placement in Accordance with Nasdaq Regulations
Private Placement Announcement: Bluejay Diagnostics, Inc. has completed a private placement of 2,250,000 shares of common stock and Series F warrants, raising $4.5 million to fund FDA approval processes and research activities.
Product Development Focus: The company is developing the Symphony System for rapid sepsis testing, with its first product candidate, an IL-6 Test, aimed at providing quick and reliable results to improve patient triage and treatment decisions.
See More
Bluejay Diagnostics Unveils $4.5 Million Private Placement Offered at Market Price According to Nasdaq Regulations
Private Placement Announcement: Bluejay Diagnostics, Inc. has entered into agreements to sell 2,250,000 shares of common stock and Series F warrants to purchase up to 4,500,000 shares at a price of $2.00 per share, with expected gross proceeds of $4.5 million.
Use of Proceeds: The company plans to use the net proceeds for FDA approval processes, clinical studies, research and development activities, and general working capital needs.
See More
Thursday's Major Stock Market Highlights: Morning News Summary!
Market Overview: Investors are navigating the second half of the week with a focus on significant stock market developments.
TipRanks Coverage: TipRanks provides a comprehensive list of the most notable market stories for Thursday.
See More
